EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Divya Teli, Pankti Balar, Kishan Patel, Anu Sharma, Vivek Chavda iD, Lalit Vora iD

Metabolites · 20.02.2023 · 13 (2) · 309

DOI: 10.3390/metabo13020309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 20.02.2023. Verfasst von Divya Teli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad 380009, India. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the RNA-dependent RNA polymerase (RdRp) enzyme, which is responsible for replicating the viral genome during the replication process of certain types of viruses. It works by disrupting the normal function of the RdRp enzyme, causing it to make mistakes during the replication of the viral genome. These mistakes can prevent the viral RNA from being transcribed, converted into a complementary DNA template, translated, or converted into a functional protein. By disrupting these crucial steps in the viral replication process, molnupiravir can effectively inhibit the replication of the virus and reduce its ability to cause disease. This review article sheds light on the impact of molnupiravir and its metabolite on SARS-CoV-2 variants of concern, such as delta, omicron, and hybrid/recombinant variants. The detailed mechanism and molecular interactions using molecular docking and dynamics have also been covered. The safety and tolerability of molnupiravir in patients with comorbidities have also been emphasized.

Schlagwörter

Stichwörter der Autor:innen

N4-hydroxycytidinemolnupiraviromicronpatients with comorbidityprodrug

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad 380009, India.
  • Pharmacy Department, L. M. College of Pharmacy, Ahmedabad 380009, India.
  • Department of Chemistry, University at Buffalo, Buffalo, NY 14260, USA.
  • Department Pharmaceutical Sciences, University of Massachusetts, Boston, MA 02125, USA.
  • Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380008, India.
  • School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.

ORCID-Profile: Vivek Chavda, Lalit Vora

Zitieren

APA

Teli, D., Balar, P., Patel, K., Sharma, A., Chavda, V., & Vora, L. (2023). Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. Metabolites, 13(2), 309. https://doi.org/10.3390/metabo13020309

Vancouver

Teli D, Balar P, Patel K, Sharma A, Chavda V, Vora L. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants. Metabolites. 2023;13(2):309. doi:10.3390/metabo13020309

BibTeX
@article{Teli2023,
  author = {Teli, Divya and Balar, Pankti and Patel, Kishan and Sharma, Anu and Chavda, Vivek and Vora, Lalit},
  title = {Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants},
  journal = {Metabolites},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {309},
  doi = {10.3390/metabo13020309}
}
Kostenlos starten →